Potential targeting of the tumor microenvironment to improve cancer virotherapy
In 2015, oncolytic virotherapy was approved for clinical use, and in 2017, recombinant
adeno-associated virus (AAV) delivery was also approved. However, systemic …
adeno-associated virus (AAV) delivery was also approved. However, systemic …
[HTML][HTML] In situ vaccination caused by diverse irradiation-driven cell death programs
Y Wang, Y Li, Y Yang, M Swift, Z Zhang, S Wu… - Theranostics, 2024 - ncbi.nlm.nih.gov
Interest surrounding the effect of irradiation on immune activation has exponentially grown
within the last decade. This includes work regarding mechanisms of the abscopal effect and …
within the last decade. This includes work regarding mechanisms of the abscopal effect and …
Safety, Efficacy, and Biological Data of T-Cell–Enabling Oncolytic Adenovirus TILT-123 in Advanced Solid Cancers from the TUNIMO Monotherapy Phase I Trial
SA Pakola, KJ Peltola, JHA Clubb, E Jirovec… - Clinical Cancer …, 2024 - AACR
Abstract Purpose: TILT-123 (igrelimogene litadenorepvec) is an oncolytic adenovirus armed
with tumor necrosis factor alpha and interleukin-2, designed to induce T-cell infiltration and …
with tumor necrosis factor alpha and interleukin-2, designed to induce T-cell infiltration and …
NOTCH1 Mutations Predict Superior Outcomes of Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
Q Huang, H Cao, Q Yao, X Zhou, H Li… - ImmunoTargets and …, 2023 - Taylor & Francis
Background NOTCH1 is frequently mutated in non-small cell lung cancer (NSCLC), and also
is a poor therapeutic target. It is of clinical importance to investigate the effects of NOTCH1 …
is a poor therapeutic target. It is of clinical importance to investigate the effects of NOTCH1 …